We have uploaded our data into Zenodo (DOI: <http://dx.doi.org/10.5281/zenodo.50919>).

Introduction {#sec005}
============

In 2014, there were an estimated of 450,000 people living with HIV in Thailand, with 8000 total new infections\[[@pone.0157039.ref001]\]. Since there is no definitive cure, HIV is a chronic disease requiring life-long treatment. In October 2014, new Thai National HIV/AIDS guidelines were launched which recommend initiating treatment "regardless of CD4 count"\[[@pone.0157039.ref002]\]. Early ARV initiation has public health benefits by minimizing sexual transmission of HIV\[[@pone.0157039.ref003]\], and also benefits the individual by preventing the development of serious AIDS and non-AIDS-related events\[[@pone.0157039.ref004]\]. While there is an attempt to scale up ARV for HIV infected individuals, drug accessibility remains a global challenge, especially where financial resources are constrained\[[@pone.0157039.ref005]\]. In Thailand, 100% of financial resources for HIV treatment are domestic\[[@pone.0157039.ref001]\]; the country depends mostly on generic ARV products.

Generic drugs, according to U.S. food and drug administration (FDA), are the same as their branded counterparts in dosage, strength, safety, route of administration, indication and action; in fact, they are supposed to be therapeutically equivalent. By FDA regulations, a generic drug must contain an identical amount of the active ingredient(s) as in the branded product\[[@pone.0157039.ref006]\]. The active ingredient is any component in a tablet that produces the pharmacological effect for an expected medical purpose\[[@pone.0157039.ref007]\]. However, an active ingredient is just one component of the quality requirements, and is not in itself sufficient to ensure therapeutic equivalence. The Thai FDA has guidelines for approval of generic drugs which requires evidence of product interchangeability equivalence, namely bioequivalence studies, comparative in vitro dissolution/release studies, comparative clinical studies, and comparative pharmacodynamics studies\[[@pone.0157039.ref008]\]. The World Health Organization (WHO) has a recommended survey protocol that defines specific items that relate to quality aspects of medicines, and substandard and counterfeit medicines. Substandard medicines are legal products that do not meet quality standards and specifications; they may occur as a result of human error, negligence, or resource restriction. In contrast, counterfeit or fake drugs are intentionally and fraudulently disguised regarding drug components, active ingredients, packaging and labeling, and are made illegally by non-licensed companies\[[@pone.0157039.ref009]\].

Incidents regarding poor-quality generic drugs have been regularly reported, particularly among life-saving anti-infective drugs within resource-limiting regions where there are less rigorous restrictions on procurement and sale, and less public awareness\[[@pone.0157039.ref010]--[@pone.0157039.ref012]\]. According to the U.S. Pharmacopeial Convention (USP) reports during 2003--2013, the proportion of substandard medicines in Asia was 2.9%; lower than that described in Africa and South America. However, Asia was reported to have the highest proportion of counterfeit medicines with a total number of 70 samples (out of 81 counterfeit products), representing 86% of sampled counterfeit products. Prevalence of sampled substandard medicine in Asia was 2.9% and Thailand was one of the least consistent in reporting data to a medicines quality database\[[@pone.0157039.ref013]\]. Problems associated with poor-quality drugs include increased morbidity and mortality, unnecessary adverse effects, suboptimal treatment leading to drug resistance, and also loss of confidence in health systems and waste of financial resources\[[@pone.0157039.ref014]\]. Therefore, it is very important for generic ARVs to be consistently monitored. Our study sampled generic ARV available from different sources in Thailand and assessed the quality by analyzing the pharmaceutical equivalence of the products.

Materials and Methods {#sec006}
=====================

The methodology has been reported in accordance with existing literature on medicines' quality surveys\[[@pone.0157039.ref009],[@pone.0157039.ref015]\].

Sampling from sources {#sec007}
---------------------

In order to represent ARVs distributed in Thailand, we obtained ARVs from primary hospitals participating in the National Universal Coverage program under the auspices of the National Health Security Office (NHSO), non-government organization (NGO) ARV clinics, and private drug stores. Six hundred and three primary hospitals that distributed ARVs through the NHSO (assessed data August 2011) were grouped by geographical location (North, South, East, West, and Central), and 2 hospitals from each region were randomly selected. For NGO sources, we collected ARV from the Thai Red Cross AIDS Research Center and the HIV-Netherlands-Australia-Thailand Research Collaboration (HIVNAT) pharmacies. For private sources, we bought ARV from 2 private pharmacies in Bangkok and 1 private pharmacy in Vietnam. \[[Fig 1](#pone.0157039.g001){ref-type="fig"}\] Convenience sampling was used to select these ARV in locations where the HIV prevalence is high.

![Geographic location of sampling sites in Thailand and Vietnam.](pone.0157039.g001){#pone.0157039.g001}

Selection of ARVs {#sec008}
-----------------

We selected two preferred first line ARVs (Tenofovir (TDF) 300mg and Efavirenz (EFV) 600mg) and one preferred second line ARV (Lopinavir/ritonavir (LPV/r) 200/50mg) recommended in the Thai National HIV/AIDS guidelines for this study\[[@pone.0157039.ref002]\]. Each ARV sample contained an adequate amount of tablets for Pharmaceutical analysis (at least 90 tablets), and had a shelf life extending beyond the analysis date. \[[Fig 2](#pone.0157039.g002){ref-type="fig"}\]

![Sampled drugs, ordered by site ID.](pone.0157039.g002){#pone.0157039.g002}

Collection of ARVs {#sec009}
------------------

For hospital sources, Local Pharmacists (who voluntarily collaborated with this study) were asked to randomly collect 1--3 bottles of each designated ARV from dispensing shelves. In addition, they completed a drug record form for each ARV sample, recording information including product name, dose, batch number, storage condition, manufactured date and expiry date. Pharmacists then shipped sampled ARVs along with completed drug record forms to the study team. Transportation to the analysis site was done using the Thai Express Mail Service and temperature was monitored during shipment.

For NGO ARV clinics and private sources, ARVs were bought by study coordinators. They acted as mystery shoppers and did not declare the objective of study to the seller. LPV/r (200/50mg) tablets were unavailable at 2 NGO clinics and 1 private pharmacy. Required documents including temperature assessment were not available for ARV purchased from the private pharmacies.

Pharmaceutical Analysis of ARVs {#sec010}
-------------------------------

Evaluation of ARVs quality was conducted according to standard procedures for pharmaceutical analysis described under specific product monographs, namely, Lopinavir and Ritonavir tablets, Efavirenz tablets, and Tenofovir tablets, published in the International Pharmacopeia (4^th^ edition) by WHO. To assess the quality of medicines in this study, four different parameters including identity test, quantitative assay, uniformity of mass, and dissolution were selected for ARVs analysis. Counterfeit and substandard medicines are partly associated with the absence or insufficient quantities of the active substance. Therefore, the Identity test was conducted to confirm the presence and identity of the active substance in the tested formulation. The content and strength of drug were determined by a quantitative assay of the amount of active substance in dosage form. Uniformity of mass was tested to confirm homogeneity of the amount of active substances among tablets manufactured in the same batch. Dissolution of ARVs, with the exception of Efavirenz tablets due to the lack of an official analytical method in pharmacopeia, was conducted to test the performance of the ARV tablet that the drug substance will release with an acceptable rate which greatly affects the bioavailability of the medicine. Drug analysis was performed by the Pharmaceutical Technology Service Center, Faculty of Pharmaceutical Science, Chulalongkorn University. Pharmaceutical Technology Service Center is an accredited laboratory complying with the ISO/IEC 17025:2005 and the requirements of the Bureau of Laboratory Quality Standards in the field of drug testing. Evaluation of ARV quality was based on acceptance criteria of each specification described in the drug monograph, and descriptive summary statistics were calculated using Stata 14 (Statacorp, College Station, TX, USA). Sources and storage conditions were blinded from the analysts\[[@pone.0157039.ref016]\].

This research study was approved by the Institutional Review Board, Faculty of Medicine, Chulalongkorn University since October 2013. Informed consent process is not required by the ethics committee/IRB because the study was conducted and analyzed for the medicine tablets that were collected. This study was not conducted in patients.

This research study was not conducted in collaboration with Thailand Drug Regulation Authority (Thai FDA) because one objective of this study was to create an independent medicine quality surveillance system. However, a summary of the study results will be disseminated to relevant agencies and organizations with an interesting drug safety and quality.

Results {#sec011}
=======

Forty-two batches of ARV (TDF, EFV, LPV/r) from 15 sources (10 primary hospitals, 2 NGO clinics and 3 private drug stores) were collected between January--March 2015. Temperature during shipment of ARV samples from sites to the analysis facility did not substantially exceed 30 ˚C, except for 5 shipments from primary hospitals where the temperature was over 30^0^ C for ≤2 hours. All ARV samples came in the original package and no broken pills were observed. Of 15 TDF samples collected, 10 samples (from all hospitals) were made locally in Thailand (not WHO prequalified); the rest were generics made in India (3 WHO prequalified, 1 not) and Vietnam (1 not WHO prequalified). Fifteen samples of EFV were collected. Two samples (1 each from a primary hospital and 1 from an NGO clinic) were Thai-made generics (not WHO prequalified), 1 sample was a generic made in China (WHO prequalified) and the rest were Indian-made generics (WHO prequalified). LPV/r obtained from the 10 hospital sources was a Thai-made generic formulation (not WHO prequalified). We also sampled 1 Thai-made (not WHO prequalified) and 1 Indian-made (WHO prequalified) LPV/r generic tablets from 2 private sources (Assess the WHO prequalification database at <http://apps.who.int/prequal/>)\[[@pone.0157039.ref017],[@pone.0157039.ref018]\] \[Tables [1](#pone.0157039.t001){ref-type="table"}, [2](#pone.0157039.t002){ref-type="table"} and [3](#pone.0157039.t003){ref-type="table"}\].

10.1371/journal.pone.0157039.t001

###### Lopinavir (200 mg)/Ritonavir (50 mg) drug sources and characteristics.

![](pone.0157039.t001){#pone.0157039.t001g}

  Site   Lot No.   Manufacturer   Country   Trade name            WHO Prequal.   Expiry date   Identification   \% of label amount   Uniformity of mass, %   Dissolution, % (LPV/RTV)                
  ------ --------- -------------- --------- --------------------- -------------- ------------- ---------------- -------------------- ----------------------- -------------------------- ------------ -------------
  001    W570041   GPO            THA       Lopinavir/Ritonavir   NO             21 Jan 16     Positive         102.1/100.8          -1.20                   1.64                       97.6/98.8    98.2/99.7
  002    W560404   GPO            THA       Lopinavir/Ritonavir   NO             13 Jul 15     Positive         103.2/102.4          -1.28                   1.48                       98.1/100.8   99.1/102.2
  003    W570169   GPO            THA       Lopinavir/Ritonavir   NO             17 Mar 16     Positive         102.1/103.6          -1.11                   1.25                       99.1/100.0   101.2/103.1
  004    W570175   GPO            THA       Lopinavir/Ritonavir   NO             17 Mar 16     Positive         101.0/103.3          -2.22                   2.08                       97.7/99.0    101.9/102.5
  005    W570450   GPO            THA       Lopinavir/Ritonavir   NO             17 Jul 16     Positive         99.4/101.8           -2.16                   1.07                       97.5/99.0    101.3/102.8
  006    W560432   GPO            THA       Lopinavir/Ritonavir   NO             23 Jul 15     Positive         99.0/103.0           -2.10                   1.87                       98.5/100.3   102.6/104.6
  007    W570457   GPO            THA       Lopinavir/Ritonavir   NO             20 Jul 16     Positive         98.6/101.5           -1.74                   2.05                       98.7/95.0    99.8/97.0
  008    W570152   GPO            THA       Lopinavir/Ritonavir   NO             10 Mar 16     Positive         99.4/101.4           -2.09                   1.76                       96.2/99.0    98.7/102.8
  009    W570285   GPO            THA       Lopinavir/Ritonavir   NO             15 May 16     Positive         98.4/101.0           -2.53                   1.94                       96.8/99.9    99.8/102.7
  010    W560556   GPO            THA       Lopinavir/Ritonavir   NO             22 Oct 15     Positive         97.8/101.5           -1.47                   1.70                       99.1/101.4   101.7/103.7
  011    W570169   GPO            THA       Lopinavir/Ritonavir   NO             17 Mar 16     Positive         98.2/101.2           -1.33                   1.52                       94.9/100.0   97.6/102.8
  012    8000458   Mylan          IND       Lopinavir/Ritonavir   YES            30 Jun 16     Positive         99.7/101.4           -1.69                   1.31                       93.4/96.3    98.6/102.9

**Abbreviations:** Lopinavir,LPV; Ritonavir, RTV; the Government Pharmaceutical Organization, GPO; Thailand, THA; India, IND.

10.1371/journal.pone.0157039.t002

###### Tenofovir (300 mg) drug sources and characteristics.

![](pone.0157039.t002){#pone.0157039.t002g}

  Site   Lot No.   Manufacturer   Country   Trade name          WHO Prequal.   Expiry date   Identification   \% of label amount   Uniformity of mass, %   Dissolution, %           
  ------ --------- -------------- --------- ------------------- -------------- ------------- ---------------- -------------------- ----------------------- ---------------- ------- -------
  013    A570270   GPO            THA       Tenofovir GPO 300   NO             12 Feb 16     Positive         103.0                -0.81                   1.46             102.3   103.3
  014    A562265   GPO            THA       Tenofovir GPO 300   NO             27 Jun 15     Positive         100.0                -1.84                   1.08             100.5   101.2
  015    A570273   GPO            THA       Tenofovir GPO 300   NO             12 Feb 16     Positive         101.6                -1.44                   1.26             101.1   102.8
  016    A570554   GPO            THA       Tenofovir GPO 300   NO             18 Mar 16     Positive         99.6                 -1.16                   1.17             99.6    101.5
  017    A570375   GPO            THA       Tenofovir GPO 300   NO             20 Feb 16     Positive         102.4                -1.34                   0.70             98.7    101.8
  018    A570324   GPO            THA       Tenofovir GPO 300   NO             17 Feb 16     Positive         103.4                -1.45                   0.80             99.3    101.4
  019    A570560   GPO            THA       Tenofovir GPO 300   NO             20 Mar 16     Positive         100.3                -1.42                   1.19             100.9   102.4
  020    A570322   GPO            THA       Tenofovir GPO 300   NO             13 Feb 16     Positive         98.6                 -1.08                   1.21             100.2   102.5
  021    A570557   GPO            THA       Tenofovir GPO 300   NO             19 Mar 16     Positive         98.4                 -0.79                   1.19             101.0   104.3
  022    A570742   GPO            THA       Tenofovir GPO 300   NO             22 Apr 16     Positive         97.0                 -0.82                   1.18             101.0   102.2
  023    8027079   Mylan          IND       RICOVIR             YES            31 Jul 17     Positive         102.5                -4.54                   4.47             98.2    100.9
  024    020414    STADA          VN        Tenofovir STADA     NO             02 Feb 16     Positive         100.6                -2.49                   2.05             96.9    100.9
  025    2507153   RANBAXY        IND       TEVIR               NO             31 Mar 15     Positive         98.0                 -1.42                   1.21             100.3   101.6
  026    8027079   Mylan          IND       RICOVIR             YES            31 Jul 17     Positive         98.4                 -2.61                   3.55             96.7    101.0
  027    E131707   Hetero         IND       TENOF               YES            31 Jul 15     Positive         97.5                 -2.10                   2.14             90.3    109.0

**Abbreviations:** Tenofovir, TDF; the Government Pharmaceutical Organization, GPO; Thailand, THA; India, IND; Vietnam, VN.

10.1371/journal.pone.0157039.t003

###### Efavirenz (600 mg) drug sources and characteristics.

![](pone.0157039.t003){#pone.0157039.t003g}

  Site   Lot No.      Manufacturer            Country   Trade name   WHO Prequal.   Expiry date   Identification   \% of label amount   Uniformity of mass, %   Dissolution, %        
  ------ ------------ ----------------------- --------- ------------ -------------- ------------- ---------------- -------------------- ----------------------- ---------------- ---- ----
  028    EM27186      Mylan                   IND       Efavirenz    YES            31 May 17     Positive         96.3                 -2.22                   1.25             \-   \-
  029    EM35108      Emcure                  IND       Efavirenz    YES            30 Apr 15     Positive         96.8                 -1.83                   2.21             \-   \-
  030    3027189      Mylan                   IND       Efavirenz    YES            31 May 17     Positive         96.9                 -1.86                   1.62             \-   \-
  031    3027187      Mylan                   IND       Efavirenz    YES            31 May 17     Positive         97.6                 -2.85                   1.67             \-   \-
  032    3027185      Mylan                   IND       Efavirenz    YES            31 May 17     Positive         97.3                 -2.21                   1.84             \-   \-
  033    3027486      Mylan                   IND       Efavirenz    YES            31 May 17     Positive         97.8                 -1.06                   0.80             \-   \-
  034    3031217      Mylan                   IND       Efavirenz    YES            30 Sep 17     Positive         97.6                 -1.11                   1.14             \-   \-
  035    A570303      GPO                     THA       Efavirenz    NO             10 Sep 15     Positive         95.4                 -1.56                   1.28             \-   \-
  036    3031198      Mylan                   IND       Efavirenz    YES            31 Aug 17     Positive         97.8                 -1.51                   1.83             \-   \-
  037    3031240      Mylan                   IND       Efavirenz    YES            30 Sep 17     Positive         97.7                 -1.76                   1.91             \-   \-
  038    3026355      Mylan                   IND       EFAMAT       YES            30 Apr 17     Positive         96.8                 -2.25                   2.08             \-   \-
  039    EFZ113033A   Hetero                  IND       ESTIVA-600   YES            30 Nov 16     Positive         98.9                 -0.98                   0.86             \-   \-
  040    A570845      GPO                     THA       Efavirenz    NO             22 Oct 15     Positive         95.6                 -2.08                   2.25             \-   \-
  041    Y1723        Zhejian Huahai Pharm.   CHI       STOCRIN      YES            03 Mar 16     Positive         95.6                 -1.01                   0.75             \-   \-
  042    E140542      Hetero                  IND       ESTIVA-600   YES            28 Feb 17     Positive         94.9                 -2.59                   1.02             \-   \-

**Abbreviations:** Efavirenz, EFV; the Government Pharmaceutical Organization, GPO; Thailand, THA; China, CHI; India, IND.

For ARV obtained from hospital sources, *ARV Storage conditions* were assessed from self-administered questionnaires completed by a hospital pharmacist. Nine out of 10 hospitals had air conditioned storage facilities with temperature less than 30°C. Seven out of 10 hospitals had humidity monitoring. Humidity was less than 60% relative humidity (RH) at most of the hospitals where monitoring was undertaken. There was 1 site with humidity of 67%RH. One hospital site had neither humidity nor temperature monitoring, because drugs were stored at the ARV clinic, not in pharmacy facility. NGO ARV clinics also had temperature and humidity controlled to be less than 30°C and 60%RH respectively. We could not assess storage conditions at private pharmacies. Of note, while a doctor's prescription is required for ARV dispensed at hospitals and the NGO ARV clinics, no formal prescription was needed in the private pharmacies where our ARV samples were procured.

Identification test and Chemical composition assay {#sec012}
--------------------------------------------------

The drug identities are demonstrated by the same retention time as corresponding International pharmacopeia reference standards using the relevant drug content assay. Each sample met the International pharmacopeia standard for drug content \[[Fig 3](#pone.0157039.g003){ref-type="fig"}\]. Mean drug content values, as described in \[[Table 4](#pone.0157039.t004){ref-type="table"}\], were close to 100% of the labelled amount; 99.9%/101.9% for LPV/r, 100% for TDF, and 96.9% for EFV. The standard deviations of all drug content assay values were relatively close; 1.76/0.93 for LPV/r, 2.10 for TDF, and 1.11 for EFV.

![Percent of label amount of each sampled ARV, by sampling site.](pone.0157039.g003){#pone.0157039.g003}

10.1371/journal.pone.0157039.t004

###### Descriptive statistics of drug content, uniformity of mass and dissolution tests.

![](pone.0157039.t004){#pone.0157039.t004g}

  ARV       N    \% of label amount (L.A.)   Uniformity of mass, %   Dissolution, %                                                                            
  --------- ---- --------------------------- ----------------------- ---------------- -------------------------- ----- ------- ------ ------------ ----------- -------------
  LPV/RTV   12   90.0--110.0%                97.8/100.8              103.2/103.6      99.9 (1.76)/101.9 (0.93)   ±5%   -2.53   2.08   ≥ 80% L.A.   93.4/95.0   102.6/104.6
  TDF       15   90.0--110.0%                97.0                    103.4            100.1 (2.10)               ±5%   -4.54   4.47   ≥ 80% L.A.   90.3        109.0
  EFV       15   90.0--110.0%                94.9                    98.9             96.9 (1.11)                ±5%   -2.85   2.25   \-           \-          \-

**Abbreviations:** Lopinavir,LPV; Ritonavir, RTV; Tenofovir, TDF; Efavirenz, EFV; Label amount, L.A.; Standard deviation, SD

Uniformity of mass {#sec013}
------------------

Uniformity of mass was used to assess uniformity of production batch for all the samples. The results ranged from -2.53% to 2.08% for LPV/r, -4.54% to 4.47% for TDF and -2.85% to 2.25% for EFV. All results were within the accepted values which range from -5% to 5%. The % deviation under uniformity of mass is calculated from the difference between the weight of individual unit and the average weight of the sample. The acceptance range is based on the criteria in the International pharmacopeia.

Test for dissolution {#sec014}
--------------------

For dissolution tests, the cumulative amount of drug (percentage of labelled amount) that dissolves over a period of time in a dissolution medium is measured. As shown in [Table 4](#pone.0157039.t004){ref-type="table"}, LPV/r and TDF samples comply with the international pharmacopeia dissolution test limit of ≥ 80% of the labeled amount.

There was no significant association between sources of ARV, WHO prequalification status, manufactured sites and storage conditions and the results of this pharmaceutical equivalence analysis.

Discussion {#sec015}
==========

The primary goal of this research study was to perform independent surveillance on the quality of commonly used generic ARV available for patients in Thailand. Although this could not represent whole ARV distributing in the region, the findings showed satisfactory quality of all ARV samples from different sources and types based on drug content, uniformity of mass and dissolution even though some batches (including those manufactured in Thailand) are not WHO prequalified. TDF test results varied most widely when compared to EFV and LPV/r, however all parameters were within the International Pharmacopeia standards. These wider ranges might reflect more variability in manufacturing sites of TDF, while LPV/r samples were retrieved from a smaller number of manufacturers. Although our findings are supported by previous studies\[[@pone.0157039.ref019]--[@pone.0157039.ref021]\], two samples of ARV from Thailand were found to be substandard in a USP convention database report in 2008 (<http://www.usp.org/worldwide/medQualityDatabase>) \[[@pone.0157039.ref022]\]. Therefore, continuous monitoring is required to ensure that products used in National Treatment Programs meet the quality standards necessary to ensure an effective and safe response to HIV. In addition, counterfeit medicines, particularly anti-malarials have frequently been found when reviewing the quality of medicines in Southeast Asian countries \[[@pone.0157039.ref011],[@pone.0157039.ref012]\], and WHO estimates the use of counterfeit drugs causes approximately 1 million deaths per year\[[@pone.0157039.ref023]\].

Although ARVs are life-saving medications, they can cause adverse events if taken incorrectly and reduce a patient's options for future treatment if they continue to be dosed in the presence of genotypic resistance. HIV care is life-long and requires multidisciplinary support, and monitoring of viral load and other safety parameters. Our finding that generic ARV could be purchased from two private pharmacies without a formal prescription, despite their supply being restricted only to hospitals and registered clinics, highlights the important public health issue of getting patients into the proper healthcare system cascade. Self-treatment with ARV, either for treatment or prevention, without proper follow up from healthcare professionals skilled in managing HIV might lead to adverse events, adherence problems, and consequently drug resistance\[[@pone.0157039.ref024]--[@pone.0157039.ref026]\]. While we promote ARV accessibility by generic importation/licensing, regulation is necessary to ensure that ARV are dispensed with a proper monitoring and follow-up system in place.

There are some limitations of our study. First, the small number of ARV samples assayed limits the power to detect any abnormalities. However, we maximized our resources by sampling ARV from primary hospitals which in theory, have the least rigorous quality control systems in place. The fact that hospital ARV samples were selected by local pharmacists, could potentially result in a "positive" selection bias Second, since there is no mechanism to check the availability of ARV in facilities outside the NHSO system, convenience sampling was used for ARV from private pharmacies and NGO's in locations where we suspected ARV would be available. This approach could miss stores in other areas who might have substandard products. Third, almost all LPV/r tablet sampled were Thai-made generics; this reflects the situation in the past when Thailand issued compulsory licenses for antiretroviral drugs including Abbott's Kaletra®, to cope with the enormous expenditure incurred by procurement of brand name ARV. Nevertheless, although Thai ARV are not WHO pre-qualified, a study has shown comparable pharmacokinetics between Thai generic and Indian generics \[[@pone.0157039.ref027]\], and the Thai FDA has rigorous standards for bioequivalence\[[@pone.0157039.ref008]\]. Finally, we were unable to include all pharmaceutical analysis methods, namely impurities and related substances, thus not allowing to us to exclude the presence of possible contaminants and resulting potential for toxicity. However, we covered the three most important components relating to bioavailability and efficacy: active ingredient, uniformity and dissolution. Some strengths of our study are also noteworthy. The collection of ARV were processed in systematic fashion. In addition, our ARV sources and storage conditions were blinded from analysts so they did not pose any bias during analysis. Lastly, while occasional surveillance of drug quality in Thailand already takes place \[[@pone.0157039.ref028]\], the surveillance might not focus on ARV. Our study is independent and focuses on commonly used ARV in the Thai National Treatment Program.

In conclusion, many sectors in Thailand have worked together to scale up ARV treatment; this study ensures the quality of the sampled drug being utilized, emphasizes further continuous monitoring, and at the same time, points out that ARV dispensing should occur in facility-based settings where regular follow-up and care are delivered.
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